12:00 AM
Feb 27, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Vpriv velaglucerase alfa regulatory update

Shire said EMA's CHMP issued a positive opinion recommending approval of its Lexington, Mass., manufacturing facility to produce Gaucher's disease therapy Vpriv velaglucerase alfa. Shire's Cambridge, Mass.,...

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >